Clinical Trial Update: A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating BXQ-350 in children with newly diagnosed diffuse intrinsic pontine glioma and diffuse midline glioma (H3 K27M-mutant) has been terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma
• Diffuse Midline Glioma H3 K27m-mutant

Drugs mentioned

• BXQ-350

Snippet

Sponsor: Bexion Pharmaceuticals, Inc. | Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Status: TERMINATED